Novartis adds opthalmology buyout in year-end deal spree; Tesaro gets a speedy FDA review for niraparib
Novartis is engaged in a year-end deal run, it seems. On Tuesday morning the pharma giant followed up its Conatus pact with news that it is buying Fort Worth-based Encore Vision after the biotech scored some positive early-stage data on their lead drug for presbyopia — a vision disorder that causes an inability to focus up close — boosting their ophthalmology pipeline. None of the terms were disclosed.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.